- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Kairos Pharma Ltd (KAPA)
Kairos Pharma Ltd stock price live, this page displays NYSE KAPA stock exchange data. View the KAPA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Kairos Pharma Ltd real time stock price chart below.
What Is the Kairos Pharma Ltd Stock Price Today?
The Kairos Pharma Ltd stock price today is 0.56.
What Is the Stock Symbol for Kairos Pharma Ltd?
The stock symbol for Kairos Pharma Ltd is "KAPA."
What Stock Exchange Does Kairos Pharma Ltd Trade On?
Kairos Pharma Ltd is listed and trades on the NYSE stock exchange.
Is Kairos Pharma Ltd a Good Stock to Buy?
Determining whether Kairos Pharma Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the KAPA quote. (ISIN: US48301N1046)
What Is the Kairos Pharma Ltd Stock Price Today?
The Kairos Pharma Ltd stock price today is 0.56.
What Is the Stock Symbol for Kairos Pharma Ltd?
The stock symbol for Kairos Pharma Ltd is "KAPA."
What Stock Exchange Does Kairos Pharma Ltd Trade On?
Kairos Pharma Ltd is listed and trades on the NYSE stock exchange.
Is Kairos Pharma Ltd a Good Stock to Buy?
Determining whether Kairos Pharma Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the KAPA quote. (ISIN: US48301N1046)
0.56
0.00(-0.43%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.56
0.57
52 wk Range
0.40
2.11
KAPA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.560.57
52 wk Range
0.402.11
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
KAPA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
8.33
Upside
+1,388.09%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 8.33
(+1,388.09% Upside)
Earnings
Latest Release
Feb 25, 2026
EPS / Forecast
-0.07 / --
Revenue / Forecast
-- / --
Compare KAPA to Peers and Sector
Metrics to compare | KAPA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKAPAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.2x | −3.8x | −0.5x | |
PEG Ratio | 0.08 | −0.08 | 0.00 | |
Price/Book | 1.9x | 2.4x | 2.6x | |
Price / LTM Sales | - | 9.2x | 3.3x | |
Upside (Analyst Target) | - | 115.7% | 47.1% | |
Fair Value Upside | Unlock | 11.2% | 6.2% | Unlock |
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients with cancer, and a systemic immune modulator to address immunosuppressive activity of solid cancers; KROS 102, a GITR antagonist to increase the inhibitory regulatory Tregs functions; KROS 201 that activates the T cells using dendritic cells for the treatment of patients with glioblastoma; KROS 301, a tumor-targeting small molecule and checkpoint inhibitor with mechanisms of action resulting from blocking intranuclear localization of RelA, a key component of the NF-KB pathway, as well as targets tumor cells in RelA/p65 biomarker positive solid tumors; and KROS 401, a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13 reversing tumor associated macrophage inhibition, and blocks the IL4/IL13 cytokine immune receptors for triple negative breast cancer. It also develops ENV 105, an antibody therapeutic for the prostate cancer patients resistant to androgen-targeted therapy, which is in Phase 2 clinical trial; and ENV 205, an antibody fragment that targets mitochondrial DNA. The company was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Kairos Pharma (KAPA) Stock Price Today?
The Kairos Pharma stock price today is 0.56 USD.
What Stock Exchange Does Kairos Pharma Trade On?
Kairos Pharma is listed and trades on the New York Stock Exchange.
What Is the Stock Symbol for Kairos Pharma?
The stock symbol for Kairos Pharma is "KAPA."
What Is the Kairos Pharma Market Cap?
As of today, Kairos Pharma market cap is 12.05M USD.
What Is Kairos Pharma's Earnings Per Share (TTM)?
The Kairos Pharma EPS (TTM) is -0.30.
When Is the Next Kairos Pharma Earnings Date?
Kairos Pharma will release its next earnings report on Jun 03, 2026.
From a Technical Analysis Perspective, Is KAPA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Kairos Pharma Stock Split?
Kairos Pharma has split 0 times.
How Many Employees Does Kairos Pharma Have?
Kairos Pharma has 3 employees.
What is the current trading status of Kairos Pharma (KAPA)?
As of May 05, 2026, Kairos Pharma (KAPA) is trading at a price of 0.56 USD, with a previous close of 0.56 USD. The stock has fluctuated within a day range of 0.56 USD to 0.57 USD, while its 52-week range spans from 0.40 USD to 2.11 USD.
What Is Kairos Pharma (KAPA) Price Target According to Analysts?
The average 12-month price target for Kairos Pharma is 8.33 USD, with a high estimate of 12 USD and a low estimate of 4 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +1,388.09% Upside potential.
What Is the KAPA Premarket Price?
KAPA's last pre-market stock price is 0.59 USD. The pre-market share volume is 4,180.00, and the stock has decreased by 0.03, or 5.36%.
What Is the KAPA After Hours Price?
KAPA's last after hours stock price is 0.59 USD, the stock has decreased by 0.03, or 5.36%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.